XTNTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Xtant Medical Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.29+0.00 (+1.50%)

Close on Oct 19, 2026

Market cap: $40.82M
P/E (TTM): –
Dividend yield: –

Xtant Medical Holdings, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	134	117	91	58	55	53	65	72	83	90	59	35	33	33	30	15
Cost of Revenue	50	49	36	26	23	19	22	29	33	28	20	13	14	10	9.11	3.36
Gross Profit	84	68	55	32	32	34	43	43	50	62	39	22	19	23	21	12
Research & Development	2.10	2.39	1.34	0.92	0.87	0.66	0.93	1.70	2.44	3.41	2.55	1.44	0.57	–	–	–
Selling, General & Admin	75	78	64	38	35	34	44	46	56	60	42	26	26	27	25	17
Selling & Marketing	46	49	38	23	21	21	26	31	41	44	29	17	16	16	19	8.90
General & Administrative	29	29	26	15	14	14	17	14	15	16	13	8.89	10	11	6.94	8.55
Advertising Expenses	–	–	–	–	–	–	–	–	–	0.18	0.22	0.03	0.05	0.05	0.08	–
Operating Expenses	77	80	66	39	36	35	45	104	88	70	51	29	28	28	27	21
Operating Income	7.28	-12	-10	-6.76	-3.85	-0.75	-2.25	-60	-38	-7.55	-12	-6.26	-9.01	-4.94	-6.45	-8.61
Interest Expense	3.67	4.16	2.94	1.69	1.00	5.98	5.77	10	15	12	7.73	5.66	4.65	1.86	1.16	1.65
Interest & Investment Income	0.09	–	0.15	0.03	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.28	-4.19	9.12	-1.66	-1.00	-5.98	-5.87	-10	-15	-12	-7.63	-4.24	-3.69	-2.77	3.44	-11
Merger & Restructuring Charges	–	–	–	–	–	–	–	2.97	4.68	0	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	48	18	0	0.23	0.91	0.73	0	–	–
Gain (Loss) on Sale of Assets	-0.25	0.26	0.12	0.09	0.09	0.37	0.06	-0.10	-0.01	-0.03	0.60	-0.03	0.00	–	–	–
Pretax Income	7.00	-16	-1.04	-8.42	-4.85	-6.73	-8.12	-70	-52	-19	-20	-11	-13	-7.71	-3.01	-19
Income Tax Expense	2.03	0.19	-1.70	0.07	–	0.30	0.10	–	0	0.05	-18	0	0	0	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	0.91	–	–	–	–
Net Income	4.97	-16	0.66	-8.49	-4.85	-7.02	-8.22	-70	-52	-19	-2.17	-11	-13	-7.71	-3.01	-19
EPS (Basic)(per share)	0.04	-0.12	0.01	-0.09	-0.06	-0.25	-0.63	-5.97	-34.76	-18.46	-0.24	-1.76	-2.80	-1.80	-0.80	-6.10
EPS (Diluted)(per share)	0.03	-0.12	0.01	-0.09	-0.06	-0.25	-0.63	-5.97	-34.76	-18.46	-0.24	-1.76	-2.80	-1.80	-0.80	-6.10
Shares Outstanding (Basic, Weighted)(shares)	140	134	119	94	85	28	13	12	1.51	1.06	9.06	5.95	4.53	4.24	3.89	3.22
Shares Outstanding (Diluted, Weighted)(shares)	150	134	127	94	85	28	13	12	1.51	1.06	9.06	5.95	4.53	4.24	3.89	3.22
EBITDA	13	-7.85	-6.98	-5.46	-2.52	1.33	0.89	-53	-29	-0.30	-7.19	-5.31	-8.25	-4.16	-5.70	-7.93

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 59.4%
Operating margin: -9.6%
Net margin: -10.2%
Return on equity, FY2025: 10.6%

Financial strength

Current ratio: 2.16
Debt to equity: 0.28
Debt to assets: 13.8%
Cash to current liabilities: 32.9%

Valuation

P/E ratio: –
Price to sales: 0.37
Price to book: 1.02
Dividend yield: –